Literature DB >> 19186452

Paraclinical evaluation of side-effects of Taxanes on auditory system.

M Sarafraz1, K Ahmadi.   

Abstract

Ototoxicity is one of the major causes of hearing loss and balance system disorders. Taxanes are a new group of anti-neoplastic agents used for chemotherapy; examples include Paclitaxel and Docetaxel. In this study, ototoxicity of these drugs has been evaluated in order to provide a means of adjusting the doses to avoid these complications. A prospective analytical study was carried out on 103 known cases of breast and ovarian cancer, during 2004 to 2006 (20 months), in the Otolaryngology, Head and Neck Surgery Department of Ahwaz University of Medical Sciences of Tehran. All patients (mean age 45 +/- 2.3 years) were treated with Taxanes. The first evaluation of hearing (using pure tone audiometery) was performed before starting treatment, the second in the middle of the treatment period and the last at the end of treatment. Results showed that nausea and vomiting were the most common side-effects of the drugs used. No significant side-effects of Taxanes, on the audiovestibular system, were observed. In conclusion, little information concerning the ototoxic effect of Taxanes has been reported in other studies, and, in the present investigation, no significant effect on the auditory system was found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19186452      PMCID: PMC2689535     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  8 in total

Review 1.  The taxoids. Comparative clinical pharmacology and therapeutic potential.

Authors:  E A Eisenhauer; J B Vermorken
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

2.  Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.

Authors:  Vassilis Georgoulias; Alexandros Ardavanis; Xanthi Tsiafaki; Athina Agelidou; Penelope Mixalopoulou; Ourania Anagnostopoulou; Panagiotis Ziotopoulos; Michael Toubis; Kostas Syrigos; Nikolaos Samaras; Aris Polyzos; Anna Christou; Stylianos Kakolyris; Charalambos Kouroussis; Nikolaos Androulakis; George Samonis; Dora Chatzidaki
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

3.  Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.

Authors:  K Ridwelski; T Gebauer; J Fahlke; H Kröning; E Kettner; F Meyer; K Eichelmann; H Lippert
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

4.  Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

Authors:  A I Dreyfuss; J R Clark; C M Norris; R M Rossi; J W Lucarini; P M Busse; M D Poulin; L Thornhill; R Costello; M R Posner
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

Review 5.  Docetaxel.

Authors:  J E Cortes; R Pazdur
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

6.  Peripheral neurotoxicity induced by docetaxel.

Authors:  P H Hilkens; J Verweij; G Stoter; C J Vecht; W L van Putten; M J van den Bent
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

7.  A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

Authors:  G Catimel; J B Vermorken; M Clavel; P de Mulder; I Judson; C Sessa; M Piccart; U Bruntsch; J Verweij; J Wanders
Journal:  Ann Oncol       Date:  1994-07       Impact factor: 32.976

Review 8.  Physiologically active cochlear micromechanics--one source of tinnitus.

Authors:  D T Kemp
Journal:  Ciba Found Symp       Date:  1981
  8 in total
  8 in total

1.  Postural sway, falls, and self-reported neuropathy in aging female cancer survivors.

Authors:  Peter C Fino; Fay B Horak; Mahmoud El-Gohary; Carolyn Guidarelli; Mary E Medysky; Sarah J Nagle; Kerri M Winters-Stone
Journal:  Gait Posture       Date:  2019-01-17       Impact factor: 2.840

2.  Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?

Authors:  Ayotunde J Fasunla; Nadia Harbeck; Barbara Schmalfeld; Sabina Berktold; Christina Böhner; Walter Hundt; Petra Wolf; Silke Steinbach
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

3.  Persistent mobility disability after neurotoxic chemotherapy.

Authors:  Elizabeth S Hile; G Kelley Fitzgerald; Stephanie A Studenski
Journal:  Phys Ther       Date:  2010-09-02

4.  Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach.

Authors:  Kerri M Winters-Stone; Britta Torgrimson; Fay Horak; Alvin Eisner; Lillian Nail; Michael C Leo; Steve Chui; Shiuh-Wen Luoh
Journal:  Arch Phys Med Rehabil       Date:  2011-03-02       Impact factor: 3.966

5.  Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.

Authors:  Christine Miaskowski; Steven M Paul; Judy Mastick; Mark Schumacher; Yvette P Conley; Betty Smoot; Gary Abrams; Kord M Kober; Steven Cheung; Jennifer Henderson-Sabes; Margaret Chesney; Melissa Mazor; Margaret Wallhagen; Jon D Levine
Journal:  Eur J Oncol Nurs       Date:  2017-11-07       Impact factor: 2.398

6.  Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.

Authors:  Christine Miaskowski; Judy Mastick; Steven M Paul; Gary Abrams; Steven Cheung; Jennifer Henderson Sabes; Kord M Kober; Mark Schumacher; Yvette P Conley; Kimberly Topp; Betty Smoot; Grace Mausisa; Melissa Mazor; Margaret Wallhagen; Jon D Levine
Journal:  J Cancer Surviv       Date:  2017-11-20       Impact factor: 4.442

7.  Severe tinnitus and migraine headache in a 37-year-old woman treated with trastuzumab for breast cancer: A case report.

Authors:  Yong-Zhi Liu; Hai Jiang; Yong-Hua Zhao; Qi Zhang; Shi-Chao Hao; Li-Ping Bao; Wei Wu; Zhao-Bo Jia; Hui-Chuan Jiang
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

Review 8.  Bone Health Management in the Continuum of Prostate Cancer Disease.

Authors:  Ettickan Boopathi; Ruth Birbe; Sunday A Shoyele; Robert B Den; Chellappagounder Thangavel
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.